by Bioblast Editor | Oct 8, 2020 | Biosimilars updates
Korea Biomedical Review reports Celltrion has received approval for Ph III trials of CT-P39 (proposed omalizumab biosimilar).
by Bioblast Editor | Jul 15, 2020 | Biosimilars updates
In an interview with the Centre for Biosimilars, Celltrion’s head of marketing, Byoungseo Choi reports Phase I and III trials of Celltrion’s omalizumab candidate are ongoing, and are expected to conclude by 2022.
by Bioblast Editor | Mar 30, 2020 | Biosimilars updates
BiosanaPharma releases the results of Ph I trials of BP001 (omalizumab), reporting comparability to Xolair®.
by Bioblast Editor | Jul 15, 2019 | Biosimilars updates
Celltrion announces start of Phase I Clinical trials of omalizumab biosimilar, with Phase III trials expected to begin in the first half of 2020.
by Bioblast Editor | Feb 21, 2019 | Biosimilars updates
Biosana announces approval for Phase 1 trials of biosimilar omalizumab, with results expected in the fourth quarter of 2019.
